The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease.

Sci Rep · 2023 · PMC9889342 · PMID 36720977

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

did not reach statistical significanceP = 0.058so close (0.05 < p ≤ 0.1)

Vedolizumab serum peak levels in the induction phase and clinical outcome analysis Week 2 responders has a higher median peak vedolizumab levels (190.6 μg/ml, 95% CI: 151–387) compared to non-responders (126.9 μg/ml, 95% CI: 36.9–203), however, the difference did not reach statistical significance ( P = 0.058).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.